Search results for "Immunoglobulin Fragments"

showing 8 items of 8 documents

Targeted cancer therapy through antibody fragments-decorated nanomedicines.

2017

Active targeting in cancer nanomedicine, for improved delivery of agents and diagnose, has been reviewed as a successful way for facilitating active uptake of theranostic agents by the tumor cells. The application of a targeting moiety in the targeted carrier complexes can play an important role in differentiating between tumor and healthy tissues. The pharmaceutical carriers, as main part of complexes, can be polymeric nanoparticles, micelles, liposomes, nanogels and carbon nanotubes. The antibodies are among the natural ligands with highest affinity and specificity to target pharmaceutical nanoparticle conjugates. However, the limitations, such as size and long circulating half-lives, hin…

0301 basic medicineCancer therapyPharmaceutical ScienceAntibody fragments03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsAntibodies BispecificmedicineMoietyAnimalsHumansImmunoglobulin FragmentsLiposomebiologyChemistryCancermedicine.diseaseMolecular biology030104 developmental biologyNanomedicine030220 oncology & carcinogenesisbiology.proteinCancer researchNanomedicineNanoparticlesAntibodyConjugateJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Selection and characterization of a novel agonistic human recombinant anti-Trail-R2 minibody with anti-leukemic activity

2009

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising natural anticancer therapeutic agent because through its “death receptors”, TRAIL-R1 and TRAIL-R2, it induces apoptosis in many transformed tumor cells, but not in the majority of normal cells. Hence, agonistic compounds directed against TRAIL death receptors have the potential of being excellent cancer therapeutic agents, with minimal cytotoxicity in normal tissues. Here, we report the selection and characterization of a new single-chain fragment variable (scFv) to TRAIL-R2 receptor isolated from a human phage-display library, produced as minibody (MB), and characterized for the in vitro anti-leukemic tumoricid…

Agonistmedicine.drug_classTRAIL; TRAIL-R2; minibody; anticancer therapyImmunologylymphoma; therapy; recombinant antibodyTRAILApoptosislymphomaCHO CellsCricetulusPeptide LibraryTRAIL-R2CricetinaeImmunoglobulin FragmentmedicineAnimalsHumansImmunology and Allergyrecombinant antibodyanticancer therapyReceptorCytotoxicityImmunoglobulin FragmentsPharmacologytherapyLeukemiaChemistryAnimalChinese hamster ovary cellAntibody-Dependent Cell CytotoxicityminibodyApoptosiIn vitroRecombinant ProteinsReceptors TNF-Related Apoptosis-Inducing LigandCHO CellCell cultureApoptosisImmunologyCancer researchTumor necrosis factor alphaCricetuluHuman
researchProduct

Model of a six immunoglobulin-like domain fragment of filamin A (16-21) built using residual dipolar couplings.

2012

Filamins are actin-binding proteins that participate in a wide range of cell functions, including cell morphology, locomotion, membrane protein localization, and intracellular signaling. The three filamin isoforms found in humans, filamins A, B, and C, are highly homologous, and their roles are partly complementary. In addition to actin, filamins interact with dozens of other proteins that have roles as membrane receptors and channels, enzymes, signaling intermediates, and transcription factors. Filamins are composed of an N-terminal actin-binding domain and 24 filamin-type immunoglobulin-like domains (FLN) that form tail-to-tail dimers with their C-terminal FLN domain. Many of the filamin …

Gene isoformModels Molecularanimal structuresMagnetic Resonance SpectroscopyProtein ConformationFilaminsIntegrinBiomolecular structuremacromolecular substances010402 general chemistryFilaminCell morphologyCrystallography X-Ray01 natural sciencesBiochemistryCatalysis03 medical and health sciencesColloid and Surface ChemistryContractile ProteinsHumansTranscription factorImmunoglobulin FragmentsActin030304 developmental biologychemistry.chemical_classification0303 health sciencesbiologyChemistryMicrofilament ProteinsGeneral Chemistry0104 chemical sciencesCell biologybody regionsbiology.proteinGlycoproteinJournal of the American Chemical Society
researchProduct

Baculoviral display of functional scFv and synthetic IgG-binding domains.

2000

Viral vectors displaying specific ligand binding moities such as scFv fragments or intact antibodies hold promise for the development of targeted gene therapy vectors. In this report we describe baculoviral vectors displaying either functional scFv fragments or the synthetic Z/ZZ IgG binding domain derived from protein A. Display on the baculovirus surface was achieved via fusion of the scFv fragment or Z/ZZ domain to the N-terminus of gp64, the major envelope protein of the Autographa californica nuclear polyhedrosis virus, AcNPV. As examples of scFv fragments we have used a murine scFv specific for the hapten 2-phenyloxazolone and a human scFv specific for carcinoembryonic antigen. In pri…

Genetic enhancementvirusesRecombinant Fusion ProteinsBlotting WesternBiophysicschemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent AssayVectors in gene therapySpodopteraBiochemistryViral vector03 medical and health sciencesMice0302 clinical medicineAntibody SpecificityPeptide LibraryAnimalsHumansMolecular BiologyImmunoglobulin FragmentsCells Cultured030304 developmental biology0303 health sciencesbiologyOxazoloneNuclear Polyhedrosis VirusCell Biologyrespiratory systembiology.organism_classificationMolecular biology3. Good healthCarcinoembryonic AntigenAutographa californicaIgG binding030220 oncology & carcinogenesisImmunoglobulin Gbiology.proteinBinding Sites AntibodyAntibodyHaptenBaculoviridaeHaptensViral Fusion ProteinsBiochemical and biophysical research communications
researchProduct

Depletion of alphaV integrins from osteosarcoma cells by intracellular antibody expression induces bone differentiation marker genes and suppresses g…

1999

Integrin heterodimers sharing the common alphaV subunit are receptors for adhesion glycoproteins such as vitronectin and fibronectin. They are suggested to play an essential role in cell anchoring, differentiation, and survival. Here, we describe the construction of an expression plasmid coding for an intracellular single-chain antibody against alphaV integrin subunit. Saos-2 osteosarcoma cells transfected with this DNA construct showed an approximately 70-100% decrease in the cell surface expression of alphaVbeta3 and alphaVbeta5 integrins as shown by flow cytometry. Intracellular antibody expression had no effect on the mRNA levels of alphaV integrin. Pulse chase experiments of metabolica…

Intracellular FluidSialoglycoproteinsCellIntegrinBone and Bones03 medical and health sciences0302 clinical medicineAntigens CDmedicineCell AdhesionTumor Cells CulturedHumansOsteopontinVitronectinMolecular BiologyImmunoglobulin Fragments030304 developmental biologyGlycoproteins0303 health sciencesOsteosarcomabiologyOsteoblastCell DifferentiationTransfectionIntegrin alphaVAlkaline PhosphataseMolecular biologyFibronectinsFibronectinmedicine.anatomical_structure030220 oncology & carcinogenesisEnzyme Inductionbiology.proteinMatrix Metalloproteinase 2VitronectinOsteopontinIntracellularBiomarkersMatrix biology : journal of the International Society for Matrix Biology
researchProduct

Human Oxidation-Specific Antibodies Reduce Foam Cell Formation and Atherosclerosis Progression

2011

ObjectivesWe sought to assess the in vivo importance of scavenger receptor (SR)–mediated uptake of oxidized low-density lipoprotein (OxLDL) in atherogenesis and to test the efficacy of human antibody IK17-Fab or IK17 single-chain Fv fragment (IK17-scFv), which lacks immunologic properties of intact antibodies other than the ability to inhibit uptake of OxLDL by macrophages, to inhibit atherosclerosis.BackgroundThe unregulated uptake of OxLDL by macrophage SR contributes to foam cell formation, but the importance of this pathway in vivo is uncertain.MethodsCholesterol-fed low-density lipoprotein receptor knockout (LDLR−/−) mice were treated with intraperitoneal infusion of human IK17-Fab (2.…

MaleoxidationGenetic enhancementGreen Fluorescent Proteins030204 cardiovascular system & hematologymedicine.disease_causeArticleAdenoviridaeMice03 medical and health sciences0302 clinical medicineIn vivoAnimalsHumansantibodiesMedicineScavenger receptorReceptorImmunoglobulin Fragments030304 developmental biologyFoam cellHomeodomain ProteinsMice Knockout0303 health sciencesbiologybusiness.industryMacrophagesscavenger receptorsgene therapyRecombinant Proteins3. Good healthLipoproteins LDLMice Inbred C57BLAdenoviridaeReceptors LDLImmunologyDisease ProgressionCancer researchbiology.proteinlipids (amino acids peptides and proteins)atherosclerosisAntibodyCardiology and Cardiovascular MedicinebusinessFoam CellsLipoproteinJournal of the American College of Cardiology
researchProduct

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

2011

Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies w…

medicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryMonoclonal antibodyAntibody fragmentsNeoplasm ProteinNeoplasmsDrug DiscoveryImmunoglobulin FragmentmedicineAnimalsHumansImmunoglobulin FragmentsAnti-EGFRPharmacologyChemotherapyMonoclonal antibodiebiologybusiness.industryAnimalDrug Discovery3003 Pharmaceutical ScienceAnti-VEGFCancerAntibodies MonoclonalImmunotherapymedicine.diseaseAntibody fragmentNeoplasm ProteinsAnti-HER2Clinical PracticeTreatment OutcomeExpert opinionImmunologybiology.proteinNeoplasmMonoclonal antibodiesImmunotherapyAnti-EGFR; Anti-HER2; Anti-VEGF; Antibody fragments; Monoclonal antibodiesAntibodybusinessHuman
researchProduct

Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase.

2001

The hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp), represented by nonstructural protein 5B (NS5B), has recently emerged as a promising target for antiviral intervention. Here, we describe the isolation, functional characterization, and molecular cloning of a monoclonal antibody (mAb) inhibiting the HCV RdRp. This mAb, designated 5B-12B7, binds with high affinity to a conformational epitope in the palm subdomain of the HCV RdRp and recognizes native NS5B expressed in the context of the entire HCV polyprotein or subgenomic replicons. Complete inhibition of RdRp activity in vitro was observed at equimolar concentrations of NS5B and mAb 5B-12B7, whereas RdRp activities of classica…

virusesHepatitis C virusMolecular Sequence DataBiologyViral Nonstructural Proteinsmedicine.disease_causeBiochemistryAntiviral AgentsViruschemistry.chemical_compoundMiceRNA polymerasemedicineAnimalsAmino Acid SequenceMolecular BiologyNS5BImmunoglobulin FragmentsPolymeraseSubgenomic mRNAMice Inbred BALB CBase Sequencevirus diseasesRNAAntibodies MonoclonalCell BiologyVirologyMolecular biologydigestive system diseasesEpitope mappingchemistrybiology.proteinFemaleEpitope MappingThe Journal of biological chemistry
researchProduct